(Q43902249)

English

A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: a trial of the Princess Margaret, Chicago and California Phase II Consortia

scientific article published on 17 April 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: a trial of the Princess Margaret, Chicago and California Phase II Consortia (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

0 references

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

fallopian tube cancer

1 reference

based on heuristic

inferred from title

fallopian tube carcinoma

1 reference

based on heuristic

inferred from title

author name string

H Hirte

1

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

S Lheureux

2

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

G F Fleming

3

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

A Sugimoto

4

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

R Morgan

5

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

J Biagi

6

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

L Wang

7

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

S McGill

8

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

S P Ivy

9

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

A M Oza

10

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

language of work or name

0 references

publication date

17 April 2015

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Gynecologic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

138

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

55-61

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Antiangiogenic agents as a maintenance strategy for advanced epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.009

7 January 2021

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.009

7 January 2021

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.009

7 January 2021

Incorporation of bevacizumab in the primary treatment of ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.009

7 January 2021

A phase 3 trial of bevacizumab in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.009

7 January 2021

OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.009

7 January 2021

Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.009

7 January 2021

Novel developments in angiogenesis cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.009

7 January 2021

Cediranib: a VEGF receptor tyrosine kinase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.009

7 January 2021

Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.009

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.009

7 January 2021

Use of CA-125 to Assess Response to New Agents in Ovarian Cancer Trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.009

7 January 2021

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.009

7 January 2021

Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.009

7 January 2021

Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.009

7 January 2021

VEGF-Trap: a VEGF blocker with potent antitumor effects

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.009

7 January 2021

Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.009

7 January 2021

Intravenous aflibercept in patients with platinum-resistant, advanced ovarian cancer: results of a randomized, double-blind, phase 2, parallel-arm study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.009

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.009

7 January 2021

Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.009

7 January 2021

A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.009

7 January 2021

Sunitinib: from rational design to clinical efficacy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.009

7 January 2021

A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.009

7 January 2021

A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor mo

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.009

7 January 2021

A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.009

7 January 2021

BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.009

7 January 2021

Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.009

7 January 2021

Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.009

7 January 2021

A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.009

7 January 2021

Incorporation of pazopanib in maintenance therapy of ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.009

7 January 2021

Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.009

7 January 2021

Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.009

7 January 2021

Emerging role for bevacizumab in combination with chemotherapy for patients with platinum-resistant ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.009

7 January 2021

Identifiers

10.1016/J.YGYNO.2015.04.009

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43902249&oldid=2104269475"